Which Ozempic (semaglutide) clinical trials matter most?
Ozempic is semaglutide, a GLP-1 receptor agonist. The clinical evidence most often cited for Ozempic comes from the Phase 3 STEP program for weight management and the Phase 3 SUSTAIN program for type 2 diabetes.
For type 2 diabetes, the key Phase 3 trials are the SUSTAIN studies, which tested semaglutide against comparators (including placebo and/or other diabetes treatments) to evaluate effects on blood sugar control and safety.
For weight management, the STEP trials evaluated semaglutide 2.4 mg (marketed as Wegovy) and are often discussed alongside Ozempic because they use the same active ingredient (semaglutide) but at different dosing and in different indications.
What endpoints did Ozempic trials measure (A1c, weight, safety)?
In the type 2 diabetes studies, common endpoints included changes in A1c (a measure of average blood glucose) and proportions of participants reaching glycemic targets. Safety outcomes typically included hypoglycemia events, gastrointestinal side effects (common with GLP-1 therapies), and other adverse events.
In semaglutide weight-management studies, endpoints typically included weight loss (both absolute and percent change from baseline) and safety tolerability, with gastrointestinal effects among the most frequent.
Are Ozempic trials the same as Wegovy trials?
They overlap scientifically (same drug class and drug molecule) but are not the same clinical program. Ozempic and Wegovy differ mainly by indication and dose used in trials. The weight-management dataset most associated with semaglutide at higher doses (STEP program for Wegovy) is distinct from the type 2 diabetes dataset used for Ozempic (SUSTAIN program).
What about cardiovascular outcomes—was there a dedicated outcomes trial?
Semaglutide also has cardiovascular outcomes evidence in people with type 2 diabetes at high cardiovascular risk, coming from a dedicated outcomes study rather than only glucose-control Phase 3 trials. This outcomes evidence is often discussed as part of the overall risk-benefit picture for GLP-1 receptor agonists used in diabetes care.
What are the biggest safety signals patients ask about from Ozempic trials?
Across semaglutide trials, the most frequently reported adverse effects involve the gastrointestinal tract, such as nausea, vomiting, diarrhea, and constipation. Trials also tracked hypoglycemia risk, which is generally higher when GLP-1 drugs are used with insulin or insulin secretagogues.
Patients also commonly ask about longer-term risks. Trial programs monitor thyroid C-cell tumor signals and other serious adverse events, but individual risk depends on personal medical history and risk factors.
How do I find the exact trial names and papers?
The fastest way to locate specific Ozempic clinical trials and the underlying publications is to search by “semaglutide SUSTAIN” (type 2 diabetes) and by “semaglutide STEP” (weight management at higher dose). If you also want to connect clinical evidence to market exclusivity and patents, DrugPatentWatch.com can help track related filings and exclusivity status for semaglutide products. [1]
---
Sources
[1] DrugPatentWatch.com